Immunologically modified MnFe2O4 nanoparticles to synergize photothermal therapy and immunotherapy for cancer treatment

Benqing Zhou, Qiang Wu, Meng Wang, Ashley Hoover, Xin Wang, Feifan Zhou, Rheal A. Towner, Nataliya Smith, Debra Saunders, Jun Song, Junle Qu, Wei R. Chen

Research output: Contribution to journalArticleResearchpeer-review

14 Citations (Scopus)


Immunotherapy has been a promising candidate for cancer treatment. The combination of photothermal therapy (PTT) and immunotherapy have shown to cause tumor ablation and induce host immune response. However, this strategy is often hampered by a limited immune response and undesirable immunosuppression. In this work, we developed an immunologically modified nanoplatform, using ovalbumin (OVA)-coated PEGylated MnFe2O4 nanoparticles (NPs) loaded with R837 immunoadjuvant (R837-OVA-PEG-MnFe2O4 NPs) to synergize PTT and immunotherapy for the treatment of breast cancer. The designed R837-OVA-PEG-MnFe2O4 NPs are able to elicit significant immune responses in vitro and in vivo. MnFe2O4 NPs also allowed for a reduction of systemic immunosuppression through downregulation of M2-associated cytokines. More importantly, the R837-OVA-PEG-MnFe2O4 NPs under laser irradiation effectively inhibited tumor growth and prevented lung metastases, leading to a prolonged survival time and improved survival rate. In addition, the designed multitasking MnFe2O4 NPs showed as a desirable contrast agent for magnetic resonance (MR) imaging to diagnose orthotopic breast tumor in vivo. Our work provides a novel strategy for combined PTT and improved immunotherapy in the treatment of breast and other metastatic cancers.

Original languageEnglish
Article number125239
Number of pages12
JournalChemical Engineering Journal
Publication statusPublished - 15 Sep 2020
Externally publishedYes


  • Immunoadjuvant
  • Immunotherapy
  • MnFeO nanoparticles
  • OVA
  • Photothermal therapy

Cite this